clinical trial · NCT07850765
Real-World Patient and Physician Experience With Semaglutide Across Six Emerging Markets
Novo Nordisk A/S·—·completed·n = 1,260
OverweightObesitySemaglutide
brief summary
The purpose of this study is to assess semaglutide's impact on daily life from participants and physicians experience.
started
Aug 28, 2026
primary completion
Aug 31, 2026
completion
Aug 31, 2026
last updated
Sep 30, 2026
official title
sEMa-LIFE: Unveiling Semaglutide's Impact on Daily Life - Patient and Physicians Experience Across Six Emerging Markets
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol